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SUMMARY
Background
Treatment options that improve overall symptoms of irritable bowel syndrome
with constipation (IBS-C) are lacking.
Aim
A prespecified further analysis to evaluate the efficacy and safety of linaclotide, a
guanylate cyclase C agonist, in patients with IBS-C, based on efficacy parameters
prespecified for European Medicines Agency (EMA) submission.
Methods
Two randomised, double-blind, multicentre Phase 3 trials investigated once-daily
linaclotide (290 lg) for 12 weeks (Trial 31) or 26 weeks (Trial 302) in patients
with IBS-C. Prespecified primary endpoints were the EMA-recommended co-pri-
mary endpoints: (i) 12-week abdominal pain/discomfort responders [ 30% reduc-
tion in mean abdominal pain and/or discomfort score (11-point scales), with
neither worsening from baseline, for  6 weeks] and (ii) 12-week IBS degree-of-
relief responders (symptoms ‘considerably’ or ‘completely’ relieved for  6 weeks).
Results
Overall, 803 (Trial 31) and 805 patients (Trial 302) were randomised. A signifi-
cantly greater proportion of linaclotide-treated vs. placebo-treated patients were 12-
week abdominal pain/discomfort responders (Trial 31: 54.8% vs. 41.8%; Trial 302:
54.1% vs. 38.5%; P < 0.001) and IBS degree-of-relief responders (Trial 31: 37.0% vs.
18.5%; Trial 302: 39.4% vs. 16.6%; P < 0.0001). Similarly, significantly more linaclo-
tide- vs. placebo-treated patients were responders for  13 weeks in Trial 302
(abdominal pain/discomfort: 53.6% vs. 36.0%; IBS degree-of-relief: 37.2% vs. 16.9%;
P < 0.0001). The proportion of sustained responders (co-primary endpoint
responders plus responders for  2 of the last 4 weeks of treatment) was also sig-
nificantly greater with linaclotide vs. placebo in both trials (P < 0.001).
Conclusion
Linaclotide treatment significantly improved abdominal pain/discomfort and
degree-of-relief of IBS-C symptoms compared with placebo over 12 and 26 weeks.
Trial registration: ClinicalTrials.gov (identifiers: NCT00948818 and NCT00938717).
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INTRODUCTION
Irritable bowel syndrome (IBS) is a chronic, gastrointesti-
nal disorder that affects approximately 10–15% of the
population in Europe.1–3 It is characterised by recurrent
abdominal pain or discomfort associated with defaeca-
tion or a change in bowel habit and is commonly
accompanied by features of disordered defaecation.4, 5
IBS can have a considerable impact on patient quality of
life and is associated with a substantial economic burden
of care, both in terms of healthcare resource utilisation
and work productivity.1, 6–9
Approximately one-third of patients with IBS experi-
ence constipation as their predominant bowel symptom
[IBS with constipation (IBS-C) subtype].3, 10 As with all
IBS subtypes, there is no gold standard of therapy for
IBS-C and currently available treatment options tend to
focus on the relief of individual symptoms.11 While tra-
ditional therapies, such as fibre and laxatives, may
improve constipation, they can aggravate bloating and
generally have little impact on abdominal symptoms or
overall symptom relief in comparison with placebo.12
More recently, serotonin reuptake inhibitors and seroto-
nergic agents have shown promise in IBS-C, but a vari-
able magnitude of effect and/or tolerability issues have
limited their widespread use.13, 14 For example, tegas-
erod, a 5-hydroxytryptamine receptor agonist, demon-
strated efficacy for the overall relief of IBS-C symptoms
in addition to improving abdominal pain/discomfort,
bloating and constipation,15 but as a result of cardiovas-
cular safety concerns, was withdrawn from the market in
the United States16 and was not approved in the Euro-
pean Union. Thus, there remains an unmet need for
well-tolerated and effective therapies that relieve all IBS-C
symptoms, including abdominal pain and other associ-
ated abdominal symptoms, in addition to improving
bowel function.
In spite of our increasing understanding of the hetero-
geneous pathophysiology of this multifaceted disease, the
development of new IBS treatments remains challeng-
ing.17–19 The assessment of treatment outcomes in clini-
cal trials has been based on patient ratings of symptom
severity using a variety of endpoints and questionnaires,
and in the absence of an instrument that adequately
assesses all the clinically important symptoms of IBS,
regulatory bodies, including both the United States Food
and Drug Administration (FDA) and the European Med-
icines Agency (EMA), have developed separate guidelines
for the design of Phase 3 clinical trials. These include
recommended endpoints to support labelling claims for
what they each consider to be the most important IBS
symptoms. For IBS-C, the FDA recommends combined
responder endpoints that capture abdominal pain and
constipation, whereas the EMA recommends co-primary
responder endpoints that capture abdominal pain/dis-
comfort along with an assessment of change in overall
symptoms.17, 18 As a result of the differences in end-
points recommended for inclusion in clinical trials by
the FDA and EMA, all endpoints relevant to either regu-
latory body, with separate statistical analysis plans, are
required if clinical trials are to provide the data neces-
sary for registration in different countries.
Linaclotide, a first-in-class guanylate cyclase C agonist
(GCCA), is a new therapy in development for IBS-C. By
binding to guanylate cyclase C receptors on the luminal
surface of gastrointestinal epithelial cells, linaclotide
stimulates intracellular production of cyclic guanosine
monophosphate (cGMP), resulting in chloride and bicar-
bonate secretion into the gastrointestinal lumen and,
consequently, increased fluid secretion and accelerated
intestinal transit.20–22 Linaclotide has also been shown to
reduce visceral hypersensitivity in animal models, which
may be related to cGMP modulation of afferent nerve
activity.20–22 In Phase 2 studies, linaclotide accelerated
colonic transit and emptying, improved bowel function
(including bowel movement frequency, stool consistency
and severity of straining) and reduced abdominal pain
severity, compared with placebo, in patients with IBS-
C.23, 24
The efficacy and safety of linaclotide in patients with
IBS-C has been further evaluated in two randomised,
placebo-controlled Phase 3 trials. These trials were
designed in accordance with both FDA and EMA guide-
lines for the clinical investigation of therapies for IBS,
and findings based on FDA-recommended endpoints
have been reported elsewhere.25, 26 In this paper, we
report the findings of a planned, separate analysis of
both trials based on the distinct efficacy parameters pre-
specified for EMA submission.
MATERIALS AND METHODS
Trial design
Two randomised, double-blind, placebo-controlled, par-
allel-group, multicentre Phase 3 trials (Trial 31,
NCT00948818 and Trial 302, NCT00938717) were con-
ducted in the United States and Canada between July
2009 and September 2010. The methodology and find-
ings of these trials, and the safety and efficacy outcomes
according to FDA-recommended endpoints have been
published in detail elsewhere.25, 26 Trial 31 was
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conducted at 118 out-patient clinical research centres
(111 in the United States, 7 in Canada). Trial 302 was
conducted in 102 centres in the United States.
Patients, aged at least 18 years, with IBS-C (modified
Rome II criteria) and a mean daily abdominal pain
score of at least 3.0 [11-point numerical rating scale
(NRS)] during the 2 weeks prior to starting treatment
were equally randomised to receive linaclotide 290 μg
or placebo once daily for 12 weeks (Trial 31) or
26 weeks (Trial 302). Abdominal symptoms (pain, dis-
comfort and bloating) and bowel function symptoms
(spontaneous bowel movement frequency, complete
spontaneous bowel movement frequency, stool consis-
tency and severity of straining) were assessed daily
throughout the trials by calls to an interactive voice
response system (IVRS). Safety assessments included
adverse event (AE) monitoring, clinical laboratory tests,
electrocardiogram recordings, vital sign measurements
and physical examinations.
Both trials were conducted in accordance with the
Declaration of Helsinki and good clinical practice guide-
lines. The protocols were approved by institutional
review boards at each trial centre and all patients pro-
vided informed consent before participating in any trial
procedures.
EMA analysis endpoints
A prespecified analysis of both trials, separate from the
previously reported FDA analyses,25, 26 was conducted
for EMA submission and assessed abdominal pain,
abdominal discomfort and degree-of-relief of IBS-C
symptoms. The two co-primary efficacy parameters eval-
uated in this analysis, based on EMA recommendations,
were 12-week abdominal pain/discomfort responders and
12-week IBS degree-of-relief responders.
Abdominal pain and abdominal discomfort were each
individually assessed daily using an 11-point NRS,
whereby patients were asked to rate their worst abdomi-
nal pain and their abdominal discomfort over the last
24 h on a scale from ‘0’ (none) to ‘10’ (very severe). A
12-week abdominal pain/discomfort responder was a
patient who, for at least 6 weeks out of the first 12 weeks
of treatment, had an improvement of 30% or more from
baseline in either mean worst abdominal pain score or
mean abdominal discomfort score for that week, with
neither of these scores worsening from baseline for that
week. In contrast with the FDA-recommended primary
combined responder endpoint, which includes assess-
ment of abdominal pain, the EMA-recommended co-
primary endpoint includes both abdominal pain and
discomfort, and is more closely aligned with the Rome
diagnostic criteria for IBS.4
Patient assessment of degree-of-relief of IBS symptoms
was recorded weekly via IVRS calls. Patients were asked
to rate their IBS symptoms during the past 7 days com-
pared with before the trial started using a 7-point bal-
anced ordinal scale, where ‘1’ indicated ‘completely
relieved’, ‘4’ indicated ‘unchanged’ and ‘7’ indicated ‘as
bad as I can imagine’. A 12-week IBS degree-of-relief
responder was a patient whose response to the degree-
of-relief of IBS symptoms question was ‘considerably
relieved’ or ‘completely relieved’ (i.e. a score of 1 or 2)
for at least 6 weeks out of the first 12 weeks of treat-
ment.
In Trial 302, 26-week abdominal pain/discomfort
responders and 26-week IBS degree-of-relief responders
(responders for at least 13 out of 26 weeks of treatment)
were also assessed as EMA-recommended secondary
endpoints. In both trials, sustained responder criteria
were defined as additional EMA-recommended efficacy
endpoints. Sustained responders were patients who met
the co-primary endpoints and were also responders for
at least 2 of the last 4 weeks of treatment.
Further EMA-recommended additional endpoints to
assess health outcomes included the Irritable Bowel Syn-
drome-Quality of Life (IBS-QoL)27 and EuroQoL-5
Dimensions (EQ-5D) instruments.28 IBS-QoL was self-
administered at baseline, at Week 12 and at the end of
treatment, and comprised an overall average score plus
eight subscale scores (dysphoria, interference with activ-
ity, body image, health worry, food avoidance, social
reaction, sexual and relationships). EQ-5D, self-adminis-
tered at baseline and at all subsequent visits, assessed the
following aspects of health status: mobility, self-care,
usual activities, pain/discomfort and anxiety/depression.
Responses on each of these subscales were converted to
a corresponding utility index. In a second EQ-5D com-
ponent, patients rated their health state from ‘0’ (worst
imaginable) to ‘100’ (best imaginable) using a visual ana-
logue scale (EQ-5D VAS).
Other symptoms that were assessed as secondary
endpoints for the EMA analysis – stool frequency, stool
consistency, severity of straining and abdominal bloating
– were also secondary endpoints for the FDA submis-
sion. The changes from baseline to Week 12 in these
symptoms have been previously reported in detail.25, 26
Statistical analysis
All EMA efficacy endpoint analyses for both trials were
based on the intent-to-treat (ITT) population, which
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included all randomised patients who received at least
one dose of trial drug and who completed at least one
post-randomisation primary efficacy assessment. For
both trials, the proportion of abdominal pain/discomfort
and IBS degree-of-relief responders in each treatment
group was compared using a Cochran-Mantel–Haenszel
test controlling for geographic region. The differences in
responder rates, corresponding 95% confidence intervals
(CIs) and two-sided P-values were calculated. The overall
type I family-wise error rates for testing the co-primary
and the main secondary efficacy parameters were con-
trolled at the 0.05 significance level using a three-step
serial gate-keeping, multiple comparisons procedure. An
observed case approach to missing data was applied for
responder variables and continuous efficacy variables: if
a patient did not have a score (responder/nonresponder)
for a particular Treatment Period week, the patient was
not considered a responder for that Treatment Period
week. This approach is conservative and any bias is
against treatment. A sensitivity analysis was conducted
using the last observation carried forward (LOCF) tech-
nique, which confirmed the robustness of the study
results.
IBS-QoL overall and subscale scores, and EQ-5D util-
ity score and VAS were summarised descriptively by
treatment group (mean, standard deviation, standard
error, median, range). Changes from baseline to Week 12
were analysed using an analysis of covariance (ANCOVA)
model that used treatment group and geographical
region as fixed effects and baseline values as a covariate.
Least squares (LS) mean changes from baseline for each
treatment group, difference in LS mean changes between
the linaclotide and placebo groups, corresponding CIs,
and two-sided P-values were calculated. The LOCF
approach was used to impute missing values; LOCF is
an accepted and typically used method for QoL variables,
and no bias in the results is to be expected.
Weekly change from baseline was analysed longitudi-
nally using a generalised linear model, based on the
observed cases during the Treatment Period; treatment
group, geographical region, week, week by treatment
interaction and subject were fixed effects and baseline
values were a covariate.
RESULTS
Patients
In Trial 31, 2424 patients were screened, 803 patients
randomised, 802 treated and 800 included in the
ITT population (linaclotide n = 405; placebo n = 395).
The 12-week Treatment Period was completed by
647 patients. In Trial 302, 2340 patients were screened,
805 patients randomised and treated, and 804 included
in the ITT population (linaclotide n = 401; placebo
n = 403). The first 12 weeks of the Treatment Period
were completed by 655 patients and 599 completed
26 weeks of treatment. The most common reasons for
treatment discontinuation were adverse events and with-
drawal of consent for the linaclotide group in both trials.
In the placebo groups, the most common reasons for
discontinuation were withdrawal of consent and adverse
events in Trial 31, and insufficient therapeutic response
and withdrawal of consent in Trial 302. The discontinua-
tion rate was similar to that seen in other trials in
patients with IBS-C. Full details of reasons for and num-
bers of discontinuations have been reported previ-
ously.25, 26
Overall, the majority of patients were female (approxi-
mately 90%) and white (77–78%). Mean age was
43.5 years in Trial 31 and 44.3 years in Trial 302. Demo-
graphics and baseline characteristics were similar
between treatment groups in both trials and are detailed
elsewhere.25, 26
Abdominal pain/discomfort responders
A significantly greater proportion of patients treated with
linaclotide were 12-week abdominal pain/discomfort
responders (co-primary endpoint) compared with those
treated with placebo in both trials (Trial 31: 54.8% vs.
41.8%, P < 0.001; Trial 302: 54.1% vs. 38.5%, P < 0.0001)
(Figure 1a). In addition, in both trials, an increase in the
proportion of weekly responders was observed after
1 week in all treatment groups; this response rate was
generally maintained throughout the Treatment Periods,
and was significantly greater in the linaclotide groups vs.
corresponding placebo groups (Figure 2).
In Trial 302, the proportion of 26-week abdominal
pain/discomfort responders in both treatment groups
was similar to that observed during the first 12 weeks of
the Treatment Period and was significantly higher in the
linaclotide group vs. the placebo group (53.6% vs. 36.0%,
P < 0.0001) (Figure 3a).
IBS degree-of-relief responders
The proportion of patients who were 12-week IBS
degree-of-relief responders (co-primary endpoint) was
significantly higher in the linaclotide treatment groups
than in the placebo treatment groups of both trials (Trial 31:
37.0% vs. 18.5%, P < 0.0001; Trial 302: 39.4% vs. 16.6%,
P < 0.0001) (Figure 1b).
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In Trial 31, an increase in the proportion of IBS
degree-of-relief weekly responders was observed with lin-
aclotide and placebo after 1 week of treatment (23.0%
and 8.9%, respectively, P < 0.0001 CMH test), with the
responder rate generally maintained throughout the 12-
week Treatment Period and significantly greater with
linaclotide vs. placebo at each week. A similar pattern of
significantly greater responder rate with linaclotide vs.
placebo was observed over the first 12 weeks of the
Treatment Period in Trial 302. In Trial 302, the 26-week
IBS degree-of-relief responder rate for both treatment
groups was similar to the 12-week responder rate and
was significantly higher in the linaclotide group vs. the
placebo group (37.2% vs. 16.9%, P < 0.0001) (Fig-
ure 3b).
Sustained responders
In both trials, the proportion of patients who met the
criteria for 12-week abdominal pain/discomfort and IBS
degree-of-relief sustained response (i.e. were 12-week
responders and also responders for at least 2 of the last
4 weeks of treatment) was similar to the proportion of
patients who met the co-primary endpoint criteria.
Compared with placebo, a significantly greater propor-
tion of patients treated with linaclotide were 12-week
abdominal pain/discomfort sustained responders in both
Trial 31 (53.1% vs. 41.5%, P  0.001) and in Trial 302
(53.6% vs. 38.0%, P < 0.0001) (Figure 4a). In Trial 302,
51.9% of linaclotide-treated patients vs. 33.3% of pla-
cebo-treated patients (P < 0.0001) were 26-week abdomi-
nal pain/discomfort sustained responders (26-week
responders plus also responders for at least 2 of the last
4 weeks of treatment) (Figure 4a).
In comparison with placebo, a significantly greater
proportion of patients treated with linaclotide vs. placebo
were 12-week IBS degree-of-relief sustained responders
in both Trial 31 (33.8% vs. 18.2%, P < 0.0001) and Trial 302
(36.7% vs. 15.6%, P < 0.0001) (Figure 4b). In Trial 302,
33.2% vs. 14.1% of patients treated with linaclotide and
placebo, respectively (P < 0.0001), were 26-week IBS
degree-of-relief sustained responders (Figure 4b).
Secondary endpoints
Compared with placebo, linaclotide was associated with
significant improvements from baseline to Week 12 in
all additional abdominal and bowel symptoms that were
assessed as secondary endpoints in both trials, as
reported elsewhere.25, 26 Data not previously reported
from these linaclotide trials are those on weekly change
in bloating severity throughout the treatment periods:
patients treated with linaclotide reported a significantly
greater decrease from baseline in bloating severity vs.
placebo over 12 weeks in Trial 31 (P < 0.0001) and over
26 weeks in Trial 302 (P < 0.0001) (Figure 5).
Health outcomes assessments
Improvements in quality of life, as assessed by arithmetic
mean change in IBS-QoL overall score from baseline to
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Figure 1 | Proportion of patients in each treatment
group who were (a) 12-week abdominal pain/
discomfort responders and (b) 12-week degree-of-relief
responders in Trial 31 and 302 (ITT population;
observed cases). **P < 0.001; ***P < 0.0001 (LIN
versus PBO, CMH test). CMH, Cochran-Mantel–
Haenszel test; IBS, irritable bowel syndrome; ITT,
intent-to-treat; LIN, linaclotide; PBO, placebo.
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groups of both trials vs. placebo (Figure 6a). In Trial 31,
the LS mean change from baseline to Week 12 was 18.4
in the linaclotide group vs. 15.2 in the placebo group [LS
mean difference = 3.3 (95% CI: 1.0, 5.5); P = 0.004] and
in Trial 302, the LS mean change from baseline to
Week 12 was 16.6 vs. 11.1 respectively [LS mean
difference = 5.5 (95% CI: 3.4, 7.6); P < 0.0001]. All IBS-
QoL subscales were improved to a significantly greater
degree following 12 weeks of treatment with linaclotide
compared with placebo in Trial 302. In Trial 31, all sub-
scales showed a significant difference between linaclotide
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Figure 2 | Abdominal pain/discomfort responders by week in (a) Trial 31 and (b) Trial 302 (ITT population; observed
cases). N = ITT population; n = number of patients with available data. P < 0.0001 (LIN vs. PBO, CMH test) at each
week of the Treatment Period. CMH, Cochran-Mantel–Haenszel test; ITT, intent-to-treat; LIN, linaclotide; PBO,
placebo.
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IBS-QoL interference with activity subscale score
(P = 0.61) at Week 12 (Table 1).
Linaclotide was also associated with greater improve-
ments in EQ-5D utility index and EQ-5D VAS com-
pared with placebo in both trials, as demonstrated by
greater arithmetic mean changes from baseline to Week 12
(Figure 6b–c). Differences between treatment groups for
the LS mean change from baseline to Week 12 in
EQ-5D utility index were significant in Trial 31 [0.08 vs.
0.05; LS mean difference = 0.03 (95% CI: 0.01, 0.05),
P = 0.001] and Trial 302 [0.08 vs. 0.04; LS mean
difference = 0.03 (95% CI: 0.01, 0.05), P = 0.0005]. For
EQ-5D VAS, the difference between treatments was sig-
nificant in Trial 302 [7.1 vs. 4.4; LS mean differ-
ence = 2.6 (95% CI: 0.8, 4.5), P = 0.006], but not in
Trial 31 [5.6 vs. 3.7; LS mean difference = 1.8 (95% CI:
0.1, 3.7), P = 0.06].
Safety and tolerability
Safety findings from these trials have been reported in
detail elsewhere.25, 26 In summary, the overall incidence
of AEs was 56% and 53% in the linaclotide and placebo
groups, respectively, over 12 weeks in Trial 31, and 65%
and 57% respectively, over 26 weeks in Trial 302.
Diarrhoea was the most common AE, reported by
19.5% vs. 3.5% of linaclotide- and placebo-treated
patients, respectively, over 12 weeks in Trial 31 and by
19.7% vs. 2.5% of patients, respectively, over 26 weeks in
Trial 302. Severity was generally mild-to-moderate and
relatively few patients who received linaclotide vs. pla-
cebo discontinued as a result of diarrhoea (5.7% vs. 0.3%
in Trial 31 and 4.5% vs. 0.2% in Trial 302). Serious AEs
(SAEs) were experienced by fewer than 2% of patients in
either treatment group of both trials and there were no
SAEs related to diarrhoea.
DISCUSSION
This prespecified further analysis of two randomised,
placebo-controlled Phase 3 trials was planned to evaluate
the efficacy and safety of linaclotide in patients with IBS-C
based on EMA-recommended endpoints. Our findings,
combined with the previously published results from the
FDA-recommended endpoints in these trials,25, 26 consis-
tently demonstrate that treatment with linaclotide was
associated with significant and sustained improvements
in abdominal, bowel and overall symptoms over 12 and
26 weeks in a typical IBS-C patient population.
EMA guidance for the evaluation of therapies for IBS
recommends that change in overall symptoms and in
abdominal pain/discomfort should be assessed as co-pri-
mary endpoints. To determine efficacy, statistically sig-
nificant results should be found with both co-primary
endpoints.17 Here, we report that, in comparison with
placebo, a significantly greater proportion of patients
treated with linaclotide in these two trials met the crite-
ria for abdominal pain/discomfort responders and IBS
degree-of-relief responders. The threshold for abdominal
pain/discomfort response in the present trials was an
improvement of at least 30% from baseline in either
score with neither worsening. An improvement in pain















































Figure 3 | Proportion of patients in each treatment
group who were (a) 26-week abdominal pain/
discomfort responders and (b) 26-week IBS degree-of-
relief responders in Trial 302 (ITT population; observed
cases). ***P < 0.0001 (LIN vs. PBO, CMH test). CMH,
Cochran-Mantel–Haenszel test; IBS, irritable bowel
syndrome; ITT, intent-to-treat; LIN, linaclotide; PBO,
placebo.
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Figure 4 | Proportion of patients in each treatment group who were (a) sustained abdominal pain/discomfort and (b)
sustained IBS degree-of-relief responders in Trial 31 and 302 (ITT population; observed cases). **P < 0.001;
***P < 0.0001 (LIN vs. PBO, CMH test). CMH, Cochran-Mantel–Haenszel test; IBS, irritable bowel syndrome; ITT,
intent-to-treat; LIN, linaclotide; PBO, placebo.
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considered to be a clinically meaningful change, as sup-
ported by an examination of the relationship between
pain intensity and overall assessments of change in
chronic pain trials.29 Response to linaclotide was sus-
tained throughout both trials, although a decrease in the
proportion of patients responding to the weekly IVRS
questions at Week 26 led to a lower proportion of IBS
degree-of-relief responders at Week 26 in both treatment
groups in Trial 302. The reason for patients missing the
weekly IVRS questions at Week 26 was due to a meth-
odological limitation allowing patients a 3-day window
for clinic visits. Many patients attended the end of trial
visit before the last IVRS call (i.e. 1–3 days before the
end of the final treatment week). The IVRS was termi-
nated upon the final clinic visit, resulting in missed IBS
degree-of-relief assessments for this final treatment week
for such patients. Nonetheless, the difference in respon-
der rates between the linaclotide and placebo treatment
groups was significant throughout the entire 26-week
Treatment Period of Trial 302 for IBS degree-of-relief.
The proportion of patients meeting the sustained respon-
der criteria was also significantly higher in the linaclotide
groups of both trials vs. placebo. Furthermore, the clini-
cal relevance of the co-primary efficacy findings of the
present EMA analysis is supported by the improvements
seen in health outcomes, which showed significant
improvement for linaclotide compared with placebo in
the IBS-QoL overall score and the EQ-5D in both trials.
In separate planned analyses of these trials, linaclotide
showed significant improvement over placebo in the
FDA-recommended primary combined responder end-
points, which were distinct from the EMA-recommended
co-primary endpoints.25, 26 Linaclotide also showed sig-
nificant improvements vs. placebo in all secondary
abdominal and bowel function parameters, including
mean scores for worst abdominal pain score, abdominal
discomfort, abdominal bloating, stool consistency and
severity of straining and mean number of spontaneous
and complete spontaneous bowel movements per week
(P < 0.0001 in both trials).25, 26 Furthermore, in Trial 31,
patients rerandomised from linaclotide to placebo at the
end of the 12-week Treatment Period showed recurrence
of symptoms to the level of placebo in the Treatment
Period, but no evidence of a rebound effect (i.e. worsen-
ing of symptoms compared with baseline).26
In addition to the efficacy findings for linaclotide
reported here and previously,25, 26 linaclotide has shown
a similar tolerability profile to placebo. In these trials,
there were few differences between treatments in the
incidence rates for individual AEs with the exception of
diarrhoea, which was reported by approximately 20% vs.
3% of patients treated with linaclotide and placebo,
respectively.25, 26 This side effect of treatment was not
unexpected, given that linaclotide acts by stimulating the
guanylate cyclase C of gastrointestinal epithelial cells to
promote cGMP-mediated chloride and bicarbonate secre-
tion into the lumen, resulting in increased fluid secretion
and accelerated intestinal transit.20–22 Most patients who
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Figure 5 | Weekly change from baseline in bloating
severity in (a) Trial 31 and (b) Trial 302 (ITT
population, observed cases). Bloating was assessed
daily using an 11-point NRS and percent change was
calculated as weekly change multiplied by 100 divided
by baseline score. P < 0.0001 (LIN vs. PBO, generalised
linear model ANCOVA). ANCOVA, analysis of covariance;
ITT, intent-to-treat; LIN, linaclotide; NRS, numeric rating
scale; PBO, placebo.
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initiating linaclotide therapy, diarrhoea severity was gen-
erally mild-to-moderate, and patients appeared to toler-
ate this adverse effect, as evidenced by the relatively low
rate of associated discontinuations (approximately
5%).25, 26 These findings are consistent with a previous
Phase 2b study of linaclotide in patients with IBS-C24
and two Phase 3 trials in patients with chronic constipa-
tion.30 As previously reported, there were few SAEs and
no deaths in either trial.25, 26
Although linaclotide significantly improved IBS-C
symptoms compared with placebo in both agency-speci-
fied analyses, placebo response rates were variable.
Response to placebo treatment was higher when assessed
using the EMA abdominal pain/discomfort responder
endpoint (approximately 40%) than when assessed with
either the EMA IBS degree-of-relief responder endpoint
(approximately 17%) or the FDA provisional combined
abdominal pain and CSBM responder endpoint (13.2–
21.0%). High placebo response rates are commonly
reported in IBS clinical trials and can limit the probabil-
ity of demonstrating a beneficial effect of therapy; these
rates can be influenced by a number of factors, including
diagnostic criteria, duration of therapy and definitions of
response.31 This consistent finding further underlines the
importance of trial design and inclusion of multiple rec-
ommended endpoints to demonstrate therapeutic efficacy
in lieu of an accepted and validated patient-reported out-
come.
The FDA and EMA have different requirements for
data to support an application for lincensing approval of
treatments for IBS-C. This situation poses a significant
challenge for sponsors and investigators seeking to design
appropriate Phase III clinical trials. Guidance from the
FDA recommends that stool frequency is measured as a
primary endpoint along with abdominal pain in trials
evaluating therapies for IBS.18 Although assessment of
stool frequency may be considered to have the advantage
of being a more objective and readily interpretable marker
of treatment outcome, the EMA-recommended co-pri-
mary endpoints may, arguably, provide a more meaning-
ful evaluation of the impact of treatments on overall IBS
symptoms and may be more likely to distinguish thera-
pies effective in IBS-C from those effective in chronic
constipation alone. However, the potential shortcomings
of overall ratings of change parameters must also be con-
sidered, including the challenge for patients of recalling
the nature and severity of their symptoms prior to initiat-
ing treatment to compare with current symptoms.
Both the EMA and FDA recommend the assessment of
abdominal pain as a key efficacy parameter, which
reflects the fundamental clinical significance of this symp-
tom in patients with IBS.32 Patient interviews have shown
that abdominal pain, abdominal bloating, constipation
and fatigue are perceived to be the most important IBS-C
symptoms, whereas other specific constipation-related
symptoms, such as straining, incomplete evacuation and
hard stool consistency, are felt to be relatively less impor-
tant.33 In the present EMA analysis, both abdominal pain
and abdominal discomfort were assessed individually as
co-primary endpoints. The Rome criteria define discom-
fort as an uncomfortable sensation that is not described
as pain,4 but there is some doubt as to whether these
terms are distinct.18 Spiegel et al. and Fehnel et al. found
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Figure 6 | Improvements in quality of life as assessed by mean changes from baseline to Week 12 in (a) IBS-QoL
overall score, (b) EQ-5D utility index and (c) EQ-5D VAS (ITT population, LOCF). *P < 0.01; **P < 0.001;
***P < 0.0001. Mean change from baseline are presented with P-values derived from ANCOVA on the change from
baseline (LIN vs. PBO). ANCOVA, analysis of covariance; EQ-5D, EuroQoL-5 dimensions; IBS-QoL, irritable bowel
syndrome-quality of life; ITT, intent-to-treat; LIN, linaclotide; LS, least squares; PBO, placebo; VAS, visual analogue
scale.
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but their understanding of the distinction between them
varies greatly.33, 34 Although harmonisation of primary
endpoint guidance, and development of an accepted and
validated patient-reported outcome is warranted, it is
likely to remain important for clinical trials to employ
multiple endpoints, which assess different aspects of this
complex disorder, to support labelling claims.
The issues arising from conflicting guidelines from the
FDA and EMA are widely recognised, and as such, the
EMA recently announced that they are updating their
trial design guidelines for the evaluation of medicines for
IBS,17 which date from 2003. One of the aims of the
updated guideline will be to consider existing discrepan-
cies between regulatory authorities, evaluate the possibili-
ties for harmonisation and, potentially, revise the
recommendations for the appropriate endpoints for
determining the success of an IBS medication. The draft
guideline is anticipated in late 2012, and expected to
come into effect in 2013.35
CONCLUSION
When assessing a complex condition such as IBS, it is
important to include multiple efficacy endpoints to
ensure that all clinically important symptoms are cap-
tured and that the effect of treatment on the patient’s
full disease experience is measured. To incorporate end-
points recommended by often conflicting guidelines from
regulatory bodies in all territories being considered for
registration of a new therapy, it is critical at the design
stage of a clinical trial to plan outcome measures for all
relevant endpoints and to prespecify separate analyses
for different registration submissions. Here, we report
for the first time, the efficacy of linaclotide in patients
with IBS-C, based on efficacy endpoints prespecified for
EMA submission. The results of this planned further
analysis of two randomised, placebo-controlled Phase 3
trials suggest that once-daily treatment with linaclotide is
associated with sustained and significant improvements
in both abdominal pain/discomfort and degree-of-relief
of overall IBS symptoms over 12 and 26 weeks in
patients with IBS-C.
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